Evidence map›Paper›PMID 27227774›Full record

Trial reportPloS one2016

Peptides in Bronchoalveolar Lavage in Chronic Obstructive Pulmonary Disease.

Chris H Wendt, Gary Nelsestuen, Stephen Harvey, Makedonka Gulcev, Matthew Stone, Cavan Reilly

Open access · goldAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Air pollution, metabolites and respiratory health across the life-course.European respiratory review : an official journal of the European Respiratory Society · 2022
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Tryptophan catabolism in acute exacerbations of chronic obstructive pulmonary disease.International journal of chronic obstructive pulmonary disease · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Chris H WendtDepartment of Medicine, VA Medical Center, Minneapolis, MN, 55417, United States of America.
Gary NelsestuenDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, 55455, United States of America.
Stephen HarveyDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, 55455, United States of America.
Makedonka GulcevDepartment of Medicine, University of Minnesota, Minneapolis, MN, 55455, United States of America.
Matthew StoneDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, 55455, United States of America.
Cavan ReillyDivision of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, 55455, United States of America.
University of Minnesota · USMinneapolis VA Medical Center · US

Funding

Protein Biomarkers in Lung Allograft RejectionR01HL080041 · NHLBI · UNIVERSITY OF MINNESOTA · PI WENDT, CHRIS H · 2007 to 2010
$1.7M
FEASIBILITY OF RETINOIC ACID TREATMENT IN EMPHYSEMA /FORTE/-N01HR96140N01HR096140 · HR · UNIVERSITY OF MINNESOTA TWIN CITIES · PI CONNETT, JOHN E · 1999 to 2006
$1.1M
NHLBI NIH HHS N01 HR096140NHLBI NIH HHS R01 HL080041
6 · The paper itself

Abstract

backgroundChronic Obstructive Pulmonary Disease (COPD) is a heterogeneous disease with a significant public health burden. Currently there is no biomarker that identifies those at risk of developing COPD, progression of disease or disease phenotypes. We performed metabolomic profiling of bronchoalveolar lavage fluid (BALF) from COPD patients to determine if metabolites correlated with clinical measurements such as lung function, functional status and degree of emphysema.

methodsMetabolomic components of BALF from 59 subjects with COPD and 20 healthy controls were separated by reversed-phase UPLC and analyzed by ESI-ToF mass spectrometry. We used univariate analysis and multiple regression models to investigate associations between metabolomic features and various clinical variables, such as lung function, functional status as measured by the St. George Respiratory Quotient Score and emphysema as measured by the CT density mask score.

resultsWe identified over 3900 features by mass spectrometry, many consistent with peptides. Subjects with severe COPD had increased concentration of peptides compared to controls (p < 9.526e-05). The peptide concentration correlated with spirometry, specifically pulmonary function tests associated with airflow obstruction. There was no correlation with CT density, i.e. emphysema, or functional status.

conclusionsMetabolomic profiling of BALF in COPD patients demonstrated a significant increase in peptides compared to healthy controls that associated strongly to lung function, but not emphysema or functional status.

Indexed as

MetabolomicsAdultAgedBronchoalveolar Lavage FluidCase-Control StudiesChromatography, LiquidFemaleHumansMaleMiddle AgedPeptide FragmentsPulmonary Disease, Chronic ObstructiveRespiratory Function TestsSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationYoung AdultPeptide Fragments

Identifiers

PMID27227774
PMCPMC4881978
OpenAlexW2405129691

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.